CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.

Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Joshua Gustine, Lian Xu, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Jiaji Chen, Xia Liu, Manit Munshi, Maria Luisa Guerrera, Gloria Chan, Christopher Patterson, Andrew Keezer, Kirsten Meid, Toni Dubeau, Guang Yang, Zachary Hunter, Steven Treon, Jorge Castillo
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research